论文部分内容阅读
目的探讨复方苦参注射液联合FOLFOX4方案(奥沙利铂+氟尿嘧啶+亚叶酸钙)治疗晚期胃癌的疗效以及安全性。方法将2010年3月-2013年1月我院104例晚期胃癌患者随机分为两组各52例,观察组接受复方苦参注射液联合FOLFOX4方案治疗,对照组患者仅接受FOLFOX4方案治疗,分析两组疗效、不良反应发生率。结果观察组近期疗效显著优于对照组,骨髓抑制、肝功能损伤、神经毒性、腹泻便秘等不良发症发生率显著低于对照组,组间差异有统计学意义(P<0.05),两组患者恶心呕吐发生率无统计学差异(P>0.05)。结论 FOLFOX4方案上联合复方苦参注射液治疗晚期胃癌疗效更佳、不良反应发生率更低,值得临床推广。
Objective To investigate the efficacy and safety of compound Kushen injection combined with FOLFOX4 regimen (oxaliplatin + fluorouracil + leucovorin) in the treatment of advanced gastric cancer. Methods From March 2010 to January 2013, 104 patients with advanced gastric cancer in our hospital were randomly divided into two groups of 52 cases. The observation group received compound Kushen injection combined with FOLFOX4 regimen, while the control group received only FOLFOX4 regimen. Two groups of curative effect, the incidence of adverse reactions. Results The curative effect of the observation group was significantly better than that of the control group. The incidence of adverse events such as bone marrow suppression, hepatic injury, neurotoxicity and constipation of diarrhea was significantly lower than that of the control group, with significant difference between the two groups (P <0.05) The incidence of nausea and vomiting in patients had no statistical difference (P> 0.05). Conclusion FOLFOX4 regimen combined with compound Kushen injection for the treatment of advanced gastric cancer is more effective and the incidence of adverse reactions is lower, which is worthy of clinical promotion.